d , Cell death quantification (% trypan blue + ) of glucose-deprived shCtrl and shGDH1 Huh7 cells treated with Tempol (25 M) or Trolox (100 M) for 72 h
8): a reduced derivative, 200 mg dose of dhBBR exhibits 9.4-fold higher plasma exposure in a randomized, double-blind, crossover fashion with five males (BBR AUC: D200: 929 vs B500: 42.3 ng/mL 120 min) with dose-linear pharmacokinetics in humans comparing with 500 mg dose of BBR (BBR level: B500: 0.4 0.17 ng/mL, D100: 3.76 1.4 ng/mL, D200: 12.0 10.1 ng/mL) [218, 219]
This fine, unflavoured powder mixes easily into water, juice, smoothies, or can be encapsulated for convenient daily supplementation
When commencing B12 replacement therapy, it is essential to recognise that pre-existing joint conditions will not resolve with vitamin supplementation alone and may require separate rheumatological assessment and management according to NICE guidelines